CDC Panel Recommends Lifting Pause On J&J Vaccine

There are 15 known cases of blood clots out of the nearly eight million people who've received this shot. Three people have died.

Video Transcript

JAY STRUBBERG: An advisory panel to the CDC is recommending the US resume its use of the Johnson & Johnson COVID vaccine after it got pulled over safety concerns. The panel says the benefits outweigh the risks, but also wants to add a warning label about rare blood clots. The CDC and FDA will make the final call about lifting the pause. Some new information from today's review. There are 15 known cases of blood clots out of the nearly 8 million people who've received the shot. Three people have died. All of these cases, known as TTS, were found in women, most of whom are between 18 and 49 years old. Symptoms are said to occur typically one to two weeks after vaccination.

TOM SHIMABUKURO: So to sum up, TTS is rare but clinically serious and potentially life threatening, in a potentially life-threatening adverse event that has been observed in association with the Janssen COVID-19 vaccine.